7.5 C
New York
Friday, April 19, 2024

Tekmira Pharmaceuticals, Lakeland Industries Moving On Possible Ebola Case In California

Courtesy of Benzinga.

Related TKMR
Falcon Edge Takes Passive Stake In Tekmira Pharmaceuticals
Morning Market Gainers
Tekmira Pharmaceuticals: Spinning Its Next 'Big Story' (Seeking Alpha)

Related LAKE
Benzinga's Top #PreMarket Losers
Morning Market Losers
GeoInvesting's Maj Soueidan Positions For 2015: An Outstanding Year For Micro-Cap Investors (Seeking Alpha)

Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR) and Lakeland Industries, Inc.'s (NASDAQ: LAKE) shares were on the move Thursday afternoon, reacting to the news of a patient being treated for possible Ebola symptoms in Sacramento County, California.

According to Dignity Health, the company that runs the first hospital that the patient attended, the patient is now being treated in the UC Davis Medical Center, which "is specifically equipped to care for patients suspected of having or diagnosed with Ebola as part of the public health department's preparedness plan."

Tekmira manufactures a therapeutic targeting the Ebola-Guinea virus. Shares were recently trading at $26.23, up 2.6 percent.

Lakeland was down about 1.4 percent, but saw a big spike up midday. The company manufactures and sells safety garments and accessories like disposable/limited use protective clothing, high-end chemical protective suits and reusable woven garments.

Related Link: The Market Doesn't Fear Ebola: A Technical Look At Lakeland Industries

Both these stocks moved intensely during the last Ebola scare, peaking in the first half of October, before falling back in the second half of the month.

In heavy trading, both stocks were reaching about half their 30-day average trading volume by 2:15 p.m. EST.

Posted-In: California Ebola Ebola-GuineaNews Intraday Update Movers

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,353FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x